Emerald Investment Advisers LLC Takes $2.21 Million Position in AtriCure, Inc. $ATRC

Emerald Investment Advisers LLC acquired a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 79,102 shares of the medical device company's stock, valued at approximately $2,213,000. Emerald Investment Advisers LLC owned approximately 0.16% of AtriCure as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock worth $46,000 after acquiring an additional 429 shares during the last quarter. Scotia Capital Inc. raised its stake in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company's stock worth $1,328,000 after buying an additional 457 shares during the period. ProShare Advisors LLC lifted its holdings in AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company's stock worth $349,000 after acquiring an additional 543 shares in the last quarter. Captrust Financial Advisors grew its stake in AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company's stock valued at $314,000 after acquiring an additional 579 shares during the period. Finally, Mackenzie Financial Corp grew its stake in AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company's stock valued at $545,000 after acquiring an additional 683 shares during the period. Institutional investors own 99.11% of the company's stock.

Insider Activity at AtriCure

In other news, Director Maggie Yuen sold 3,500 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karen Prange sold 3,564 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director owned 22,809 shares in the company, valued at $884,989.20. The trade was a 13.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 44,246 shares of company stock worth $1,691,895. Corporate insiders own 4.00% of the company's stock.

AtriCure Trading Up 3.1%

NASDAQ ATRC opened at $48.98 on Friday. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $49.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock's 50 day moving average price is $35.83 and its two-hundred day moving average price is $31.84. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of 233.25 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts anticipate that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ATRC shares. Citigroup reiterated a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday. Zacks Research upgraded shares of AtriCure from a "hold" rating to a "strong-buy" rating in a report on Friday, July 24th. Finally, Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source